RECRUITING

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Description

Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.

Conditions

Radial Artery Occlusion
Talk to us

Related Conditions:

Radial Artery Occlusion

Study Overview

On this page

Study Details

Study overview

Coronary angiography is performed to evaluate for obstructive coronary artery disease. This is commonly performed via the transfemoral or transradial approach with the latter increasing in frequency. One of the most common complications of transradial access is radial artery occlusion occurring in \~5% of patients which prohibits the use of the radial artery in the future. There is evidence to support the use of intraprocedural anticoagulation to mitigate the risk of radial artery occlusion however the role of post-procedural anticoagulation has not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this has on the rate of radial artery occlusion.

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

Condition
Radial Artery Occlusion
Intervention / Treatment

-

Contacts and Locations

Rochester

Mayo Clinic, Rochester, Minnesota, United States, 55905

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Willing and able to provide written informed consent
  • 2. Age ≥ 18 years
  • 3. Diagnostic coronary angiography or percutaneous coronary intervention via the transradial approach
  • 1. Presence of a palpable hematoma or clinical concern of hemostasis at the transradial access site
  • 2. Access or attempted access at a second site - including contralateral radial artery, brachial, or femoral artery or vein
  • 3. Planned staged procedure, CABG or noncardiac surgery within 30 days
  • 4. Contraindication or high risk of bleeding with anticoagulation
  • 1. bleeding requiring medical attention in the previous 6 months
  • 2. thrombocytopenia (platelets\<50 x 109/L)
  • 3. prior intracranial hemorrhage
  • 4. use of IIb/IIIa during percutaneous coronary intervention
  • 5. administration of thrombolytic therapy in the preceding 24 hours
  • 6. use of non-steroidal anti-inflammatory medications
  • 7. ischemic stroke or transient ischemic attack diagnosed in the last 3 months
  • 5. Cardiogenic shock
  • 6. Ventricular arrhythmias refractory to treatment
  • 7. Liver dysfunction (Child-Pugh class B or C)
  • 8. Unexplained anemia with a Hgb below 100 g/L
  • 9. History of medication noncompliance or risk factor for noncompliance
  • 10. Active malignancy
  • 11. Allergy to rivaroxaban
  • 12. Another indication for anticoagulation
  • 13. CYP3A4 and P-glycoprotein inhibitor use
  • 14. Life expectancy \<30 days
  • 15. Women capable of pregnancy not on birth control
  • 16. Chronic kidney disease with creatinine clearance of less than 30mL/min
  • 17. History of antiphosphopholipid antibody syndrome

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ottawa Heart Institute Research Corporation,

Study Record Dates

2026-06-30